Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) with a report date of September 15, 2016, covering events occurring on September 15 and September 19, 2016. The filing addresses the company's status regarding its listing on the NYSE MKT.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes
- Regulatory Compliance: On September 15, 2016, the company received written notice from NYSE MKT LLC confirming it is back in compliance with continued listing standards under Section 1003(f)(v) of the NYSE MKT Company Guide.
- Monitoring Status: The company is now subject to normal continued listing monitoring by NYSE Regulation.
- Future Risk: If the company falls below listing standards again within 12 months, NYSE MKT will re-evaluate the financial recovery from the first incident and may truncate compliance procedures or immediately initiate delisting.
Guidance, Outlook, and Risks
Management issued a press release on September 19, 2016, announcing the regained compliance. The primary risk identified is the potential for immediate delisting or truncated compliance procedures if the company fails to maintain listing standards within the next 12 months.
Investor Verification Checklist
- Verify the company name is Hemispherx Biopharma, Inc., not AIM Immunotech Inc.
- Confirm the specific listing standard (Section 1003(f)(v)) that was previously violated and is now satisfied.
- Review the attached press release (Exhibit 99.1) for additional details on the compliance path.
- Monitor future filings for any indication of renewed noncompliance within the 12-month window.